Predavatelji / Speakers – Seminar III

Predavatelji / Speakers

Dr. Lumír Ondřej Hanuš

Palacký Univerza v Olomouc-u, Češka
Hebrew University of Jerusalem, Izrael

Lumír Ondřej Hanuš je češki analitični kemik in vodilna avtoriteta na področju raziskovanja konoplje. Leta 1992 je skupaj z William-om Anthony Devane-om izoliral in prvi opisal strukturo anandamid, endogeni kanabinoidni nevrotransmiter.
Prejemnik številnih nagrad na področjih kemije in medicine (Memorial Medal, Doctor honoris causa, Jack Herer Award, Outstanding Immigrant Scientist…).
V letih 2010 in 2011 je sodeloval na seminarjih v češkem parlamentu, osredotočenih na vzpostavitev zdravljenja s kanabinoidi.

Lumír Ondřej Hanuš, PhD

Palacký University Olomouc, Czech Republic
Hebrew University of Jerusalem, Israel

Lumír Ondřej Hanuš is a Czech analytical chemist and leading authority in the field of cannabis research. In 1992, he and William Anthony Devane isolated and first described the structure of anandamide, an endogenous cannabinoid neurotransmitter. Recipient of numerous awards in the fields of chemistry and medicine (Memorial Medal, Doctor honoris causa, Jack Herer Award, Outstanding Immigrant Scientist ).
In 2010 and 2011 he participated in seminars in the Czech Parliament, focused on the establishment of treatment with cannabinoids.

Povzetek predavanja
OD KONOPLJE DO UPORABE V SODOBNI MEDICINI
Predavanje se posveča zgodovini konoplje in odkritjem aktivnih gradnikov v konoplji in možganih ter njihovi uporabi v medicini po svetu. Posebna pozornost bo namenjena prednostim in potencialnim slabostim te zdravilne rastline.

Abstract
FROM THE HEMP TO ITS PRESENT MEDICAL USE
The lecture is devoted to the history and discoveries of active compounds in the hemp and brain and to its worldwide medical use. Stressed are advantages and possible disadvantages of this medical plant.

Dr. Paul Hornby

Raziskovalec
predsednik Hedron Analytical Inc. Vancouver, British Columbia, Kanada

Paul Hornby je diplomiral iz zoologije, je magister biokemije in doktoriral pa je na področju človeške patologije.
Je ustanovitelj in predsednik laboratorija, ki analizira kemično sestavo zeliščnih pripravkov. Health Canada mu je podelila certifikat za vodenje laboratorija, ki lahko legalno analizira konopljo, profile kanabinoidov in kemično sestavo.

Je avtor številnih študij in člankov v zvezi s konopljo (kemična sestava konoplje, metode ekstrakcije aktivnih kanabinoidov).

Paul Hornby, PhD

Researcher
President Hedron Analytical Inc., Vancouver, British Columbia, Canada

Paul Hornby has a B.SC. degree in zoology, a M.SC. degree in biochemistry and a PhD in human pathology.
He was the founder and president of Hedron Analytical Inc., a small company providing chemical analyses of herbal preparations. He has been granted authority by Health Canada for a laboratory that can legally analyze cannabis for it’s cannabinoid profile and chemical content.

He is the author of numerous studies and articles relating to cannabis (hemp, chemical composition, method of extraction of active cannabinoids).

Povzetek predavanja
ABC O CBD OZ. POMEN KANABIDIOLA
Kanabidiol (CBD) bo v prihodnosti nosil večji medicinski potencial kot tetrahidrokanabinol (THC), čeprav za zdravljenje veliko bolezni delujeta sinergistično; CBD je izredno učinkovit že z majhnimi količinami THC-ja.
Največja razlika med THC in CBD-jem je ta, da je THC psihoaktivna substanca, ki lahko vodi do potencialno neprijetnih (vendar ne nevarnim) predoziranj, medtem ko CBD takšnih učinkov nima.
Kanabidiol je klinično dokazano izjemen antioksidant s protivnetnim delovanjem, lajša bolečine ter opazno zmanjšuje anksioznost.
Kanabidiol (CBD) se običajno priporoča kot dnevno zdravilo za jasnost misli, osredotočenost in zaradi anksiolitične lastnosti, kakor tudi proti raku in zaradi protivnetnih in protikonvulzivnih (epilepsija) učinkov..

Delavnica
DEKARBOKSILACIJA IN STANDARDIZACIJA
Na delavnici bomo natančneje spoznali proces in pomen dekarboksilacije in standardizacije produktov iz konoplje za medicinske namene.

Abstract
THE ABC OF CBD OR THE IMPORTANCE OF CANNABIDIOL
Cannabidiol (CBD) holds a greater medical future than Tetrahydrocannabinol (THC) although they work synergistically in being effective against many illnesses; CBD has a profound efficacy with only small amounts of THC needed.
The greatest difference between THC and CBD is that THC is psychoactive and can lead to a potentially unpleasant (non-fatal) overdose, whereas this effect does not occur with CBD. Cannabidiol has been shown clinically to be a powerful anti-oxidant and anti-inflammatory and also brings about pain relief with a marked reduction in anxiety.
Cannabidiol (CBD) is normally recommended as a daytime medicine for mental clarity, focus and anxiolytic properties as well as anti-cancer, anti-inflammatory and anti-convulsent (epilepsy) effects.

Workshop
DECARBOXILATION AND STANDARDIZATION
The workshop will focus on the process and importance of standardization and decarboxylation of cannabis for medical purposes.

Dr. Robert J. Melamede

Izredni profesor, Oddelek za biologijo
Univerza v Koloradu – Colorado Springs, ZDA
Cannabis Science, predsednik in direktor

Robert J. Melamede je doktoriral iz molekularne biologije in biokemije na City University v New Yorku in je vodilna avtoriteta na področju uporabe kanabinoidov za terapevtske namene.
Je avtor številnih znanstvenih publikacij, predavatelj ter strokovni član številnih združenj in fundacij (International Association for Cannabis as Medicine, Scientific Advisory Board of Americans for Safe Access, Sensible Colorado, Cannabis Therapeutics).

Robert J. Melamede, PhD

Associate Professor, Department of Biology
University of Colorado – Colorado Springs, USA
Cannabis Science, President and Director

Dr. Robert Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects.
Member of several scientific boards (International Association for Cannabis as Medicine, the Scientific Advisory Board of Americans for Safe Access, Sensible Colorado, Scientific Advisor for Cannabis Therapeutics).

Povzetek predavanja
ŽIVLJENJE, EVOLUCIJA, ENDOKANABINOIDI IN PREŽIVETJE HOMO SAPIENSA
Termodinamika – čeprav daleč od ravnovesja – zagotavlja temelje za razumevanje življenja, evolucijo in edinstveno vlogo, ki jo je endokanabinoidni sistemu igral v teh procesih. Kanabinoidi lahko urejajo presnosvne temelje življenja z namenom spodbujanja zdravja in dolgega življenje. To počnejo z regulacijo negativnih učinke prostih radikalov, ki nastajajo s presežno proizvodnjo, s pomočjo lastne sposobnostjo nadzorovanja presnove maščob in ogljikovih hidratov. Povečanje kanabinoidnih dejavnosti je potrebno za zdravje sodobnega človeka in človeške družbe. Konoplja je postala bistveno hranilo.

Delavnica
EVOLUCIJA, PRILAGODLJIVOST IN KANABINOIDI
Na delavnici bomo podrobneje spoznali delovanje in pomen kanabinoidov.

Abstract
LIFE, EVOLUTION, ENDOCANNABINOIDS AND THE SURVIVAL OF HOMO SAPIENS
Far from equilibrium thermodynamics provides a foundation for understanding life, evolution, and the unique role played by the endocannabinoid system in these processes. The metabolic underpinnings of life can be regulated by cannabinoids in order to promote health and longevity. They do so by regulating the negative effects of excess free radical production through their ability to control fat and carbohydrate metabolism. An increase in cannabinoid activity is necessary for the health modern man and human society. Marijuana has become an essential nutrient.

Workshop
EVOLUTION, ADAPTABILITY AND CANNABINOIDS
The workshop will focus on functioning and importance of cannabinoids.

Dr. Sue Sisley

Docentka, Medicinska fakulteta – Univerza v Arizoni, ZDA
Pomočnica direktorja za medstrokovno izobraževanje, Arizona Telemedicine Program, Phoenix
Glavna raziskovalka, FDA odobrena raziskava o varnosti in učinkovitosti medicinske konoplje pri veteranih s kroničnim in na zdravila odpornim PTSM

Suzanne A. “Sue” Sisley je psihiatrinja in docentka Medicinske fakultete na Univerzi v Arizoni. Poznana je predvsem zaradi raziskav o potencialih uporabe konoplje v medicini.
Bolnikom zagotavlja klinično oskrbo s pomočjo telemedicine, katere tehnologija vključuje videokonference iz satelitskih klinik ter spremljanje daljinskih naprav v uporabi na domu za psihiatrična vrednotenja, spremljanje zdravljenja z zdravili ter psihiatrične storitve v sili.
Kot lečeča zdravnica telemedicine uči študente medicine/prebivalce v sklopu tedenskih gostovanj na telemedicinskih klinikah, ki se nahajajo na 170 različnih lokacijah v Arizoni, ZDA.

Sue Sisley, PhD

Assistant Professor, Clinical Faculty – University of Arizona Collegeof Medicine, Tucson, Arizona
Arizona Telemedicine Program, Assistant Director of
Interprofessional Education, Phoenix, AZ
Principal Investigator, FDA-Approved Investigation of the
Safety and Efficacy of Medical Marijuana in Veterans with
Chronic, Treatment-Resistant PTSD

Suzanne A. “Sue” Sisley is a psychiatrist and former clinical assistant professor at the University of Arizona College of Medicine. She is known for her research into potential medical uses of marijuana.
Provides clinical care directly to patients through Telemedicine technology including videoconferencing from satellite clinics and home remote monitoring devices for Psychiatric Evaluations, Medication Monitoring and Emergency Psychiatry, including Title 36 services.
Teaches Medical Students/Residents as Telemedicine Attending Physician for weekly Telemedicine Clinic serving 170 different sites around state of AZ, USA.

Povzetek predavanja
MEDICINSKA UPORABA KONOPLJE ZA ZDRAVLJENJE BOLNIKOV Z ODPORNIMI OBLIKAMI POST-TRAVMATIČNE STRESNE MOTNJE (PTSM)
Medicinska uporaba konoplje za zdravljenje bolnikov z na zdravila odpornimi oblikami post-travmatične stresne motnje (PTSM), ki je podprta s številnimi viri, vključno z laboratorijskimi raziskavami na živalih, fMRI slikanji pri ljudeh kot tudi pričanji in poročili neštetih zdravstvenih delavcev in bolnikov. Ocene kliničnih raziskav zdravljenja PTSM s konopljo v Izraelu so obetavne. Nova študija, ki bo potekala v dveh 3-tedenskih fazah, bo preizkušala 4 sorte konoplje. Vsaka izmed njih bo vsebovala različne vsebnosti aktivnih kanabinoidov, ki bodo uporabljena kot farmakološka sredstva za obvladovanje simptomov PTSM med 80-imi ameriškimi vojnimi veterani. Študija je plod sodelovanja med dr. Sisley in raziskovalci iz univerz iz Hopkinsa, Kolorada in Pensilvanije. Bo prva randomizirana, kontrolirana in navzkrižna klinična raziskava v ZDA, ki bo preizkušala terapevtski potencial konoplje za PTSM. Primarni rezultati raziskave bodo razvrščeni v klinično vodeno lestvico PTSM (CAPS-5). Obsežni sekundarni rezultati pa bodo vsebovali še vzorce spanja, depresijo, odtegnitvene simptome, presnovne in vnetne panele in samo-poročanje bolnikov.

 

Delavnica
MEDICINSKA UPORABA KONOPLJE ZA ZDRAVLJENJE POST-TRAVMATIČNE STRESNE MOTNJE (PTSM)
Na delavnici bomo natančneje spoznali:
- obstoječe/trenutno stanje glede anekdotičnih in merljivih načinov zbiranja podatkov
- ozadje oblikovanja prve randominizirane, trojno slepe in kontrolirane študije za oceno uporabe konoplje pri PTSM
- regulativne ovire pri vodenju znanstvene študije in razvoju medicinske konoplje v odobreno zdravilo po FDA (Food and Drug Administration)
- hipotezo mehanizmov delovanja uporabe medicinske konoplje pri zdravljenju PTSM.

 

Abstract
THE USE OF MEDICAL MARIJUANA TO TREAT PATIENTS WITH TREATMENT-RESISTANT POST-TRAUMATIC STRESS DISORDER (PTSD)
The use of medical marijuana to treat patients with treatment-resistant Post-Traumatic Stress Disorder (PTSD) is supported by a number of sources, including research in lab animals, fMRI imaging in humans, and anecdotal reports from countless health practitioners and patients. Additionally, clinical research in Israel evaluating medical marijuana as treatment for PTSD has been promising. This study will test four strains of smoked marijuana, each containing different concentrations of active cannabinoids, in two three-week stages, as a pharmacological agent to manage PTSD symptoms among 80 American war veterans. This study is a collaboration between me and researchers from Johns Hopkins University, University of Colorado, and University of Pennsylvania. This will be the first randomized controlled crossover clinical trial in the United States testing the therapeutic potential of marijuana for PTSD. The primary measured outcome will be the Clinician Administered PTSD Scale (CAPS-5), alongside extensive secondary outcomes including sleep patterns, depression, withdrawal symptoms, metabolic and inflammation panels, and self-reporting by the patients.

Workshop
THE USE OF MEDICAL MARIJUANA TO TREAT PATIENTS WITH TREATMENT-RESISTANT POST-TRAUMATIC STRESS DISORDER (PTSD)
At the workshop we will learn about:
- existing/current state of both anecdotal & observation data
- the design of the first ever triple blind randomized controlled trial evaluating use of Marijuana for military-related PTSD.
- about regulatory obstacles to conducting this scientific study and developing medical marijuana
- hypothesized mechanisms of action for use of MMJ in treatment of military-related PTSD.

Dr. Ilya Reznik

Specialist za odrasle na področju forenzične in klinične nevropsihiatrije v diagnostičnem in svetovalnem centru MaReNa, Izrael

Dr. Ilya Reznik je avtor odličnih izobraževalnih in strokovnih zapisov in dokumentiranih prispevkov na področju nevropsihiatričnih raziskav, kot so publikacije in druge inovativne dejavnosti.

Dr. Reznik redno objavlja avtorske študije (vključno z nadzorovanimi testiranji), preglede in poročila o posameznih primerih v vodilnih strokovnih revijah na področju klinične psohiatrije in nevropsihofarmakologije. Glavno področje delovanja je uporaba konoplje in kanabinoidov za medicinske namene, predvsem za različne nevropsihiatrične bolezni, kot so sindrom kronične bolečine, posttravmatske stresne motnje (PTSM), obsesivno-kompulzivne motnje, Tourettov sindrom, Parkinsonova bolezen, Alzheimerjeva bolezen itd..

V zadnji 6-ih letih koordinira aktivnosti Nacionalnega foruma/Združenja za raziskave in zdravljenje s konopljo v Izraelu. Bil je pridruženi član kanadskega Konzorcija za raziskovanje kanabinoidov (PKSI), član mednarodnega raziskovalnega združenja za kanabinoide (ICRS). Leta 2013 je bil izvoljen v odbor Mednarodnega združenja za kanabinoidna zdravila (IACM), kjer spodbuja izobraževalne in mednarodne dejavnosti IACM.

Ilya Reznik, PhD

Board-certified specialist in Adult Forensic & Clinical
NeuroPsychiatry at MaReNa Diagnostic and Consulting
Center, Israel

Dr. Ilya Reznik has superior educational and professional record and documented contributions to the field of neuropsychiatric research, such as publications and other innovative activities.
Dr. Reznik has published many original papers (including controlled trials), reviews and case reports in leading peer-reviewed journals in field of clinical psychiatry and neuropsychopharmacology. His current main interest is in the field of the medical use of cannabis and cannabinoids, especially for various neuropsychiatric illnesses, such as Chronic Pain Syndrome, Post-Traumatic Stress Disorder (PTSD), OCD, Tourette syndrome, Parkinson’s and Alzheimer
diseases etc.

During last 6 years he coordinates the activity of Israel National Forum/Association for Medical Cannabis Research & Treatment. He is Associate Member of The Canadian Consortium for the Investigation of Cannabinoids (CCIC), Member of International Cannabinoid Research Society (ICRS). In 2013 he was elected to Board of Directors, International Association for Cannabinoid Medicines (IACM) and promotes educational and international activity within IACM.

Povzetek predavanja
PRAKTIČNI VIDIKI UPORABE KONOPLJE KOT ZDRAVILNE UČINKOVINE
Marihuana, botanično poznana kot konoplja, je z nami približno tisoče let. Zdravilne in rekreativne uporabe konoplje so znane iz antičnih časov in konoplja je bila v uporabi kot legalna zdravilna rastlina do 1937-1941. Od takrat je bila marihuana razvrščena na seznam nadzorovanih snovi prve skupine, promet z njo (v kakršnikoli obliki) pa je bil razglašen kot nezakonit in prepovedan.
V zadnjem desetletju so se nekatere evropske (Nizozemska, Španija, Nemčija, Avstrija), ameriške (Kanada, nekatere države v ZDA) in druge države po svetu (Izrael), dogovorile, da se ponovno prizna pozitivne lastnosti marihuane in njeno uporabo za nekatera zdravstvena stanja/indikacije pa dekriminalizira. Kljub temu, široko (in rastoče) uživanje konoplje med prebivalstvom, predvsem za rekreacijske namene, povečuje povpraševanje po boljši opredelitvi konoplje kot zdravila in drugo uporabo konoplje v različnih oblikah. Mednarodne klinične in regulativne izkušnje, zbrane v državah, kjer so programi uporabe konoplje za medicinske namene že uveljavljeni, je treba skrbno in sistematično raziskovati in kritično ocenjevati, da bi natančno določili boljše (v smislu nadzora kakovosti in dostopnosti) modele za zmanjšanje javne stigmatizacije, ustrezno izobraževanje strokovnjakov na področju zdravstvenega varstva in spodbujanja uporabe konoplje za medicinske namene.
Glede na številne lastne klinične izkušnje na tem področju, bomo na kratko pregledali obstoječe programe uporabe konoplje za medicinske namene, ogledali predloge, govorili o praktičnih nasvetih o smotrni (previdni in varni) uporabi konoplje kot dragocene medicinske snovi, zlasti za bolnike z različnimi nevropsihiatričnimi motnjami.

Delavnica
PRAKTIČNI VIDIKI UPORABE KONOPLJE
Na delavnici bomo podrobneje izvedeli komu se predlaga zdravljenje s konopljo in komu odsvetuje.

Abstract
PRACTICAL ISSUES ON USING CANNABIS AS A MEDICAL SUBSTANCE
Marijuana, botanically known as cannabis, has been around for thousands years. The medicinal and recreational uses of the cannabis have been known from the ancient times and marijuana was used as a legal form of the plant medicine till the1937-1941. Since that time, marijuana was included to the upper part (Schedule 1) of the list of controlled substances and its circulation (in any form) was announced as illegal and prohibited.
During the last decade some European (Holland, Spain, Germany, Austria), American (Canada, several States in the USA) and other countries (Israel), agreed to re-acknowledge the positive properties of marijuana and decriminalized it’s usage for some certain medical conditions/indications. Nevertheless, the wide (and growing!) spreading of cannabis consumption among the population, mostly for recreational purposes, enhances the demand for better definition between medicinal and other usage of various forms of cannabis. The international clinical and regulatory experience, accumulated in the countries, already established the Medical Cannabis/Marihuana Programs, should be carefully and systematically studied and critically assessed, in order to elaborate the better (in the means of the Quality Control and Accessibility) model(s) for the reducing of public stigma, proper education of the health care professionals and to promoting medicinal uses of the cannabis.
Based on my large clinical experience in this field, I will review (in short) the current Medical Cannabis/Marihuana Programs and will provide some suggestions and practical tips on wise (careful and safe) usage the Cannabis as a valuable Medical substance, especially for the patients with the various neuropsychiatric disorders.

Workshop
PRACTICAL ISSUES ON USING CANNABIS AS A MEDICAL SUBSTANCE
The workshop will provide insight to whom treatment with cannabis should be suggested and to whom, probably, not.

Mag. Dušan Nolimal

Nacionalni inštitut za javno zdravje
Predstavnik Slovenije v skupini Pompidou pri Svetu Evrope
Nacionalni koordinator za področje drog pri WHO

Dušan Nolimal je zdravnik in specialist socialne medicine z organizacijo zdravstvenega varstva (javnega zdravja). Subspecializiral je iz področja epidemiologije in raziskovanja prepovedanih drog v Denverju, Kolorado, ZDA na University of Colorado School of Medicine ter Nacionalnem inštitutu za droge (NIDA), v Baltimorju, Maryland, ZDA.
Je priznan predavatelj iz področja epidemiologije in preprečevanja bolezni odvisnosti ter krepitve psihosocialnega zdravja.

Dušan Nolimal, MD, MSPH

National Institute of Public Health
Representative of Slovenia at the Pompidou group, Council of Europe
National Coordinator for drugs in the WHO

Dušan Nolimal is a doctor and specialist in social medicine and the organization of health care (public health care system).
Specialised in the field of epidemiology and research on illicit drugs in Denver, Colorado, USA at the University of Colorado School of Medicine and the National Institute on Drugs (NIDA), in Baltimore, Maryland, USA.
Is recognized lecturer in the field of epidemiology and prevention of substance abuse and strengthening psychosocial health.

Povzetek predavanja
ZNANOST, ETIKA IN POLITIKA RAZVRŠČANJA PREPOVEDANIH DROG
V zadnjih nekaj letih se je znanstveno, politično in javno znanje precej spremenilo, nedavne razprave o razvrščanju nekaterih drog, zlasti konoplje, pa so privedle do vprašanj o jasnosti, zanesljivosti in etiki sedanjega sistema in ali je le-ta še primeren. Znanstveni dokazi in soglasje o tem, da trenutna klasifikacija konoplje v sistemu Združenih narodov predstavlja zgodovinsko anomalijo in da ga je potrebno pregledati v čim krajšem možnem času. Trdi se, da konoplja nima velike možnosti za zlorabo, ki je potrebna za uvrstitev med najbolj nevarne droge. Prav odkritje receptorjev kanabinoidnega sistema v poznih 1980-ih je revolucionariziralo znanstveno razumevanje učinkov konoplje, in ponudilo dodatne dokaze, da ima potencialne pozitivne zdravstvene učinke.
UNGASS o drogah 2016 ponuja priložnost za ponovno preučitev teh vprašanj. Upa(j)mo, da se bo upoštevalo znanstvene ugotovitve v zvezi z varnostjo in učinkovitostjo konoplje pri nekaterih zdravstvenih stanjih, kot tudi dokaze o možnih zdravstvenih tveganjih, povezanih z uživanjem konoplje, zlasti v obliki kajenja. ZN bi morali voditi nacionalne sisteme za nadzor drog in njihove klasifikacije – vključno z vsemi psihoaktivnimi rastlinami in snovmi (dovoljenimi ali nedovoljenimi) – na podlagi znanosti, etike in človekovih pravic, sicer bo verodostojnost takšnih pristopov ogrožena.

Abstract
SCIENCE, ETHICS AND POLITICS IN CLASSIFYING THE DANGERS OF DRUGS
Over the past years the scientific, political and public knowledge have changed quite significantly and recent debates about the classification of certain drugs, especially cannabis, have led to questions about the clarity, reliability and ethics of the current system and whether it remains fit for purpose. The scientific evidence and consensus are growing that the current classification of cannabis in the UN system represents a historical anomaly and should be reviewed at the earliest opportunity. It has been argued that cannabis lacks the high abuse potential required for inclusion among the most dangerous drugs. Also, the discovery of the cannabinoid receptor system in the late 1980s revolutionized scientific understanding of cannabis’ effects and provided further evidence that it has potential beneficial medical effects.
The 2016 UNGASS on drugs provides an opportunity to re-examine these issues. We hope this re-examination will consider the scientific findings regarding cannabis’s safety and efficacy in some medical conditions as well as evidence on the possible health risks associated with cannabis consumption, particularly in its smoked form. The UN should guide national drug control and classification systems to be predominantly science, ethics and human rights informed, including all psychoactive plants and substances (whether licit or illicit), otherwise the credibility of such approaches will be undermined.

Božidar Radišič

ONEJ – Društvo prekmurske pobude, Slovenija
Član IACM – International Association for Cannabinoid Medicines

Božidar Radišič je predstavnik društva ONEJ v mreži nevladnih organizacij na področju drog v Sloveniji in član mednarodne zveze za kanabinoidna zdravila IACM. Redno se udeležuje in predava na seminarjih in drugih dogodkih, povezanih s konopljo tako v Sloveniji kot tujini. Domača in mednarodna javnost ga pozna predvsem kot neutrudnega aktivista za konopljo in zagovornika uporabnikov medicinske konoplje v Sloveniji.

Božidar Radišič

ONEJ – Association of Prekmurje Initiative, Slovenia
Member of IACM – International Association for Cannabinoid Medicines

Božidar Radišič is a representative of ONEJ in network of NGO’s in the field of drugs in Slovenia and a member of IACM – International Association for Cannabinoid Medicines. He regulary lectures and participates at seminars and other events on cannabis in Slovenia and abroad. National and international public knows Božidar as a tireless activist and medical cannabis advocate in Slovenia.

Povzetek predavanja
UPORABA KONOPLJE V SLOVENIJI IN IZKUŠNJE
Uporaba konoplje in njenih derivatov je zelo razširjena med slovenskimi bolniki, zlasti med obolelimi za rakom in nevrološkimi bolniki. Zaradi vedno večjega števila poročil o “čudežnih” ozdravitvah, smo se odločili, da začnemo spremljati bolnike, ki želijo deliti svoje izkušnje z nami; zaradi verodostojnosti, smo se odločili, da zberemo njihove zdravstvene kartoteke.
Predavanje je skupek izkušenj, ki temeljijo na intervjujih z bolniki in njihovih pričevanjih, ter podprto z zdravstveno dokumentacijo.

Abstract
CANNABIS USE IN SLOVENIA AND EXPERIENCES
The use of cannabis and its derivatives is widespread among the Slovene patients, especially among cancer and neurological patients. Due to the increasing number of reports on “miraculous” healings, we have decided to start monitoring patients who would like to share their experience with us; for the sake of credibility, we have decided to gather their medical records.
The lecture is a set of experiences based on interviews with patients and their testimonies. All this is supported by medical records.

Maja Kohek

ONEJ – Društvo prekmurske pobude, Slovenija
ENCOD – European Coalition for Just and Effective Drug Policies

Maja Kohek, univ. dipl. kulturologinja in socialna antropologinja je aktivna v številnih organizacijah v Sloveniji in tujini. Na področju drog sodeluje predvsem z društvom Onej, kot članica Encoda-a pa je aktivna tudi na evropski ravni. Ukvarja se predvsem z raziskovanjem uporabe konoplje in drugih prepovedanih drog (tako v medicinske kot rekreativne namene) ter s sodno prakso v povezavi z drogami v Republiki Sloveniji.

Maja Kohek

ONEJ – Asscociation of Prekmurje Initiative, Slovenia
ENCOD – European Coalition for Just and Effective Drug Policies

Maja Kohek is a cultural and social anthropologist, active in many organizations in Slovenia and abroad. In the field of illicit drugs she collaborates with Association ONEJ and is a member of ENCOD (European Coalition for Just and Effective Drug Policies). Her interest lies in the research of use of cannabis and other illicit drugs (for medicinal and recreational purposes) and drug use related law in the Republic of Slovenia.

Delavnica
KRATKA ANALIZA STANJA NA PODROČJU ZAKONODAJE DO KONOPLJE V RS
Delavnica je namenjena vsem, ki želijo izvedeti več o zakonodaji na področju prepovedanih drog v Republiki Sloveniji. Razpravljali bomo o obstoječi zakonodaji, sodni praksi in metodah zagovorništva.

Workshop
A BRIEF ANALYSIS OF CANNABIS POLICY IN THE REPUBLIC OF SLOVENIA
The workshop is meant for those who wish to learn about legislation on illicit drugs in the Republic of Slovenia. We will discuss the existing legislation, jurisprudence and methods of advocacy.

http://onej.info
onej.info@gmail.com
+ 386 (0)41 208 289